Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage.
Recent evidence has suggested that the delayed cerebral ischemic deficits that often follow surgery for aneurysmal subarachnoid hemorrhage (SAH) may be due to a proliferative vasculopathy. This vascular pathology may result from an interaction between the platelets and the vessel wall. A single-blind controlled trial of dipyridamole administration in 677 patients presenting with SAH (of whom 348 came to surgery) was undertaken to test the hypothesis that the modification of platelet behavior might reduce the incidence of ischemic deficits. Blind independent assessment of the outcome in the surgical group based on the Glasgow Outcome Scale and the specific neurological deficits revealed no significant differences between the control and treatment groups.
D001792:Blood Platelets / Q000187:drug effects; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000627:therapeutic use*; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications / Q000601:surgery*; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000209:etiology; D010919:Placebos; D011897:Random Allocation; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000601:surgery*
D010919:Placebos; D004176:Dipyridamole